Compare NVCR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | ARDX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2015 | 2014 |
| Metric | NVCR | ARDX |
|---|---|---|
| Price | $15.80 | $5.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $28.08 | $15.14 |
| AVG Volume (30 Days) | 1.5M | ★ 3.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $655,353,000.00 | $2,607,000.00 |
| Revenue This Year | $7.72 | $37.75 |
| Revenue Next Year | $6.74 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.28 | N/A |
| 52 Week Low | $9.82 | $3.54 |
| 52 Week High | $19.25 | $8.40 |
| Indicator | NVCR | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 33.34 |
| Support Level | $12.48 | $5.49 |
| Resistance Level | $18.80 | $6.23 |
| Average True Range (ATR) | 0.87 | 0.26 |
| MACD | -0.39 | -0.10 |
| Stochastic Oscillator | 5.46 | 0.50 |
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.